Chemotherapy Resistant Cell Lines

With a self-developed technology, we have generated derivatives of a number of cancer cell lines
(HeLa SiHa, CaSki, C33, HaCaT, MCF7, PANC-1, BxPC-3, AsPC-1, MIA PaCa-2), resistant to gemcitabine, cisplatin, 5-FU and doxorubicin, useful to study the mechanisms of resistance and cancer stem cells.

Oligonucleotides

We have developed and patented modified derivatives of gemcitabine AP-111 and AP-112 (European Patent EP No. 2 854 864 B1)
useful for in vitro and in vivo studies on pancreatic ductal adenocarcinoma and its derivative cell lines.